Suppr超能文献

局部疼痛管理与 5%利多卡因药膏——综述。

Topical pain management with the 5% lidocaine medicated plaster--a review.

机构信息

Center for Pain Evaluation and Treatment, University Neurological Hospital, Lyon, France.

出版信息

Curr Med Res Opin. 2012 Jun;28(6):937-51. doi: 10.1185/03007995.2012.690339. Epub 2012 May 24.

Abstract

BACKGROUND

The topical 5% lidocaine medicated plaster is recommended as first-line treatment for localized peripheral neuropathic pain.

SCOPE

In order to provide an overview of the efficacy and safety of the lidocaine plaster in the treatment of different neuropathic pain conditions, all efficacy and safety studies (randomized, controlled, or open-label with well described methodology), case reports, and pharmacological studies on the lidocaine plaster retrieved from a PubMed literature research (1960-March 2012) plus additional references identified from retrieved articles were included.

FINDINGS

The lidocaine plaster is efficacious in the treatment of neuropathic pain symptoms associated with previous herpes zoster infection. Results from a large open-label controlled study suggest that the lidocaine plaster could be at least as effective as systemic pregabalin in the treatment of postherpetic neuralgia and painful diabetic polyneuropathy. Open-label studies indicate efficacy in the treatment of other localized neuropathic pain conditions, such as painful idiopathic sensory polyneuropathy, complex regional pain syndrome, carpal tunnel syndrome sequelae, postsurgical and posttraumatic pain. Quality of life markedly improved in a variety of neuropathic pain conditions and long-term treatment provided sustained relief in patients with neuropathic pain who are responsive to lidocaine plaster. The lidocaine plaster is usually well tolerated. The risk of systemic adverse events and pharmacokinetic interactions with concomitant medication is minimal owing to low systemic exposure.

CONCLUSIONS

Treatment of several, primarily neuropathic and mixed-pain conditions with the 5% lidocaine medicated plaster was found efficacious and safe. Further controlled studies, in particular where only small open-label studies or case reports are available, should be considered.

摘要

背景

局部外周神经性疼痛的一线治疗药物为 5%利多卡因贴剂。

范围

为了全面评估利多卡因贴剂治疗不同神经性疼痛疾病的疗效和安全性,我们检索了 PubMed 文献(1960 年至 2012 年 3 月),并结合从检索文献中获取的其他参考文献,纳入了所有关于利多卡因贴剂的疗效和安全性研究(随机、对照或开放性、方法描述详尽)、病例报告和药理学研究。

结果

利多卡因贴剂治疗与疱疹后神经痛相关的神经性疼痛症状有效。一项大型开放性对照研究的结果表明,与系统用普瑞巴林相比,利多卡因贴剂治疗疱疹后神经痛和痛性糖尿病多发性神经病的疗效至少相当。开放性研究表明,其对其他局部神经性疼痛疾病也有效,如痛性特发性感觉神经病、复杂性局部疼痛综合征、腕管综合征后遗症、术后和创伤后疼痛。多种神经性疼痛疾病的生活质量显著改善,且对利多卡因贴剂有反应的神经性疼痛患者长期治疗可获得持续缓解。利多卡因贴剂通常具有良好的耐受性。由于全身暴露量低,发生全身不良反应的风险和与同时使用的药物发生药代动力学相互作用的风险极小。

结论

利多卡因贴剂治疗多种神经性和混合性疼痛疾病有效且安全。应考虑开展更多对照研究,特别是对于仅有少量开放性研究或病例报告的疾病。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验